Blood Reviews最新文献

Evaluation of current mouse in vivo models and advanced in vitro models for leukaemia research. 目前白血病研究的小鼠体内模型和先进的体外模型的评价。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-06-23 DOI: 10.1016/j.blre.2025.101318

Xenia Bubnova, Lauren Hope, Helen Wheadon

引用次数: 0

Iron chelation therapy in myelodysplastic syndromes and allogeneic hematopoietic cell transplantation, a delicate balance. 铁螯合治疗骨髓增生异常综合征和异基因造血细胞移植，一个微妙的平衡。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-06-23 DOI: 10.1016/j.blre.2025.101319

Fieke W Hoff, Eduard Schulz, Steven Pavletic, Alain Mina

引用次数: 0

Novel therapies for acute myeloid leukemia. Does age still matter? 急性髓性白血病的新疗法。年龄还重要吗？

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-06-11 DOI: 10.1016/j.blre.2025.101317

Baher Krayem, Avraham Frisch, Netanel Horowitz

{"title":"Novel therapies for acute myeloid leukemia. Does age still matter?","authors":"Baher Krayem, Avraham Frisch, Netanel Horowitz","doi":"10.1016/j.blre.2025.101317","DOIUrl":"https://doi.org/10.1016/j.blre.2025.101317","url":null,"abstract":"The prognosis of patients with AML varies significantly with age, driven by biological heterogeneity and age-associated factors such as comorbidities, functional status, and hospitalization burden. Many novel therapies have been approved in recent years; however, pivotal trials often include patients within a restricted age range, limiting the extrapolation of their findings across the broader AML population. For example, the FLT3 inhibitor midostaurin was added to chemotherapy for patients aged 18-60 years, while the BCL-2 inhibitor venetoclax was combined with azacitidine in patients aged 75 years and older, leaving important knowledge gaps regarding their efficacy and safety in other age groups. Moreover, for several novel therapies, particularly in populations outside the original trial age range, supporting evidence is derived primarily from single-arm studies or real-world experience rather than randomized controlled trials, further complicating clinical decision-making. This review explores the efficacy and safety of widely used traditional and novel therapies for AML, with particular focus on the impact of age on these different therapeutic regimens.","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":" ","pages":"101317"},"PeriodicalIF":6.9,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144303630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions. 探讨淋巴细胞恶性肿瘤低γ -球蛋白血症的深度：病理生理学、临床意义、管理选择和未来方向。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-06-10 DOI: 10.1016/j.blre.2025.101316

Alex Wonnaparhown, Talal Hilal, Albert Chong, Rafael Fonseca

引用次数: 0

Tackling myeloma bone disease: From pathophysiology to cutting-edge therapies. 治疗骨髓瘤骨病：从病理生理学到尖端疗法。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-05-24 DOI: 10.1016/j.blre.2025.101305

Sophie Roux, Françoise Debiais, Marie-Hélène Vieillard

引用次数: 0

Unmet needs in hemophilic arthropathy. 血友病关节病未满足的需求。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-05-21 DOI: 10.1016/j.blre.2025.101304

Yesim Dargaud, Sebastien Lobet, Nathalie Roussel, Leonard A Valentino

引用次数: 0

Patient-reported outcomes - the missing link to advancing light chain (AL) amyloidosis clinical research. 患者报告的结果-推进轻链（AL）淀粉样变性临床研究的缺失环节。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-05-20 DOI: 10.1016/j.blre.2025.101303

Tobias Dittrich, Lina Weinert, Anita D'Souza

引用次数: 0

The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies. 血小板在静脉血栓栓塞中的关键作用：发病机制、临床状况和新兴的治疗策略。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-05-14 DOI: 10.1016/j.blre.2025.101302

Shuang Liu, Yan Shen, Jiayi Chen, Zheng Ruan, Li Hua, Kankan Wang, Xiaodong Xi, Jianhua Mao

{"title":"The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies.","authors":"Shuang Liu, Yan Shen, Jiayi Chen, Zheng Ruan, Li Hua, Kankan Wang, Xiaodong Xi, Jianhua Mao","doi":"10.1016/j.blre.2025.101302","DOIUrl":"https://doi.org/10.1016/j.blre.2025.101302","url":null,"abstract":"Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is a complex vascular disorder with high morbidity and mortality, driven by Virchow's Triad: blood stasis, hypercoagulability, and endothelial injury. VTE is now recognized as an inflammatory process involving multiple components. Platelets are involved in the process of VTE, contributing to thrombosis initiation, progression, resolution and recurrence through coagulation activation, and interactions with immune and endothelial cells. Anticoagulation remains the cornerstone of VTE treatment; however, antiplatelet agents like aspirin have demonstrated therapeutic potential, particularly following major orthopedic surgeries. Furthermore, emerging platelet-targeted therapies and biomarkers offer new opportunities for improving VTE diagnosis and treatment. This review explores the evolving role of platelets in VTE pathophysiology, assesses current antiplatelet strategies, and highlights novel therapeutic approaches. Advancing platelet research in VTE may lead to safer, more effective interventions, optimizing outcomes for patients with this life-threatening condition.","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":" ","pages":"101302"},"PeriodicalIF":6.9,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144096012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights. 导航低风险MDS的动态景观：进展和新兴见解。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-05-14 DOI: 10.1016/j.blre.2025.101301

Alain Mina, Yazan Madanat, Yasmin Abaza, Amer M Zeidan

{"title":"Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights.","authors":"Alain Mina, Yazan Madanat, Yasmin Abaza, Amer M Zeidan","doi":"10.1016/j.blre.2025.101301","DOIUrl":"https://doi.org/10.1016/j.blre.2025.101301","url":null,"abstract":"Myelodysplastic syndromes/neoplasms (MDS) are a group of clonal myeloid malignancies characterized by ineffective hematopoiesis, cytopenias, and an increased risk of transformation to acute myeloid leukemia (AML). In lower-risk (LR) MDS, as defined by the revised and molecular international prognostic scoring systems (IPSS-R and IPSS-M), anemia is often the predominant clinical manifestation. Treatment strategies have traditionally focused on supportive care, including transfusion support and erythropoiesis stimulating agents (ESAs). While allogeneic hematopoietic stem cell transplantation remains the only potentially curative option for select patients, LR-MDS remain otherwise incurable with current therapies. With the exception of lenalidomide which was approved in 2005 in USA, therapeutic advancements in LR-MDS have stalled for almost 15 years. Progress has been limited by the disease's inherent complexity, indolent nature, and significant heterogeneity, as well as challenges in clinical trial design and execution. Recent advances in gene sequencing and molecular analyses have significantly increased our understanding of disease biology. These insights, coupled with collaborative efforts across the academic community, have led to meaningful shifts in classification, prognostication, and response assessment paradigms in LR-MDS. This evolution has led to a number of approvals, including luspatercept approved in 2020, and imetelstat, which was approved in 2024 in USA. As the therapeutic landscape of LR-MDS continues to evolve, there is growing optimism that these recent milestones will pave the way for further advancements and improved patient outcomes. Next set of studies should focus on the optimal sequencing and combinations of existing agents, as well as moving forward novel effective agents.","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":" ","pages":"101301"},"PeriodicalIF":6.9,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatments. 成人原发性免疫性血小板减少症管理的新时代：对当前和新兴治疗方法的叙述回顾。

IF 6.9 2区医学

Blood Reviews Pub Date : 2025-05-09 DOI: 10.1016/j.blre.2025.101300

Tomás José González-López, Drew Provan

引用次数: 0